Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY PFSB Draft Budget Includes ¥2.1 Bil. to Improve Review, Safety Measures
December 27, 2011
-
BUSINESS Chugai to Participate in Multinational Study of Avastin in Breast Cancer
December 27, 2011
-
REGULATORY Tougher Restrictions on Reimbursement of Vitamins to Cut ¥15 Bil. from Med. Expenditure
December 26, 2011
-
REGULATORY ¥25 Bil. to Be Saved through Add’l NHI Price Cuts for Both Long-listed, Generic Drugs in FY2012: MHLW
December 26, 2011
-
REGULATORY 0.9% Additional Price Cut for Long-Listed Drugs, Compensating Upward Revision of Nursing Fee: Minister Negotiation
December 22, 2011
-
BUSINESS Ranbaxy Settles with US FDA, Commits to Improvements in GMP Compliance, Data Integrity: Daiichi Sankyo
December 22, 2011
-
REGULATORY CSIMC Approves Additional Price Reduction for Long-listed Drugs Next Year
December 22, 2011
-
REGULATORY Price Cut Negotiations for Long-Listed Products Between MOF, Health Ministers “Parallel”
December 21, 2011
-
BUSINESS MTPC, Novartis Pharma Focused on Promoting Proper Use of MS Treatment Imusera/Gilenya
December 21, 2011
-
BUSINESS Chugai to Establish Pool System of Candidate Leaders
December 20, 2011
-
ORGANIZATION Mr Sawai of JGA Announces “Absolute Opposition” to Add’l Price Reduction for Generics
December 20, 2011
-
REGULATORY MHLW Subcommittee Agrees on Mandatory Notification of Package Inserts
December 19, 2011
-
REGULATORY Expert Subcommittee Agrees to 2-Year Continuation of Trial of Premium for New Drug Development
December 19, 2011
-
BUSINESS ReproCELL to Commercialize World’s 1st iPS Cell-Derived Hepatocytes in April
December 16, 2011
-
REGULATORY Public-Private Dialogue to Set Next Strategic Plan for Innovative Drug Discovery
December 15, 2011
-
ORGANIZATION Industry Reps Call for 4-6 Year Extension of Trial for Premium for New Drug Development
December 15, 2011
-
REGULATORY CSIMC Approves Draft Measures to Promote Generic Drug Use
December 15, 2011
-
BUSINESS MTPC to Focus on Development of Global Human Resources
December 14, 2011
-
ORGANIZATION Share of Generics Virtually Unchanged at 23.2%: JGA Flash Report
December 14, 2011
-
BUSINESS Wholesalers Eager to Begin Category-Based Price Negotiations After FY2012 Price Revision
December 13, 2011
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…